tradingkey.logo

tradingkey.logo
怜玢


Atara Biotherapeutics Inc

ATRA
りォッチリストに远加
7.700USD
-0.230-2.90%
終倀 11-13 16:00ET
77.31M時䟡総額
損倱額盎近12ヶ月PER

Atara Biotherapeutics Incに぀いお 䌁業名

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Atara Biotherapeutics Inc プロフィヌル


䌁業コヌドATRA
䌚瀟名Atara Biotherapeutics Inc
䞊堎日Oct 16, 2014
最高経営責任者「CEO」Nguyen (Anhco)
埓業員数153
蚌刞皮類Ordinary Share
決算期末Oct 16
本瀟所圚地1280 Rancho Conejo Blvd
郜垂THOUSAND OAKS
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号91320
電話番号18056234211
りェブサむトhttps://www.atarabio.com/
䌁業コヌドATRA
䞊堎日Oct 16, 2014
最高経営責任者「CEO」Nguyen (Anhco)

Atara Biotherapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Brian N. Cherry
Mr. Brian N. Cherry
Independent Director
Independent Director
166.49K
+62.57%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
26.36K
+45.52%
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Gregory A. (Greg) Ciongoli
Mr. Gregory A. (Greg) Ciongoli
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Amber Daugherty
Mr. Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Mr. James Huang
Mr. James Huang
Independent Director
Independent Director
--
--
Mr. Nachi Subramanian
Mr. Nachi Subramanian
Independent Director
Independent Director
--
--
Mr. Kevin Sarney
Mr. Kevin Sarney
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Brian N. Cherry
Mr. Brian N. Cherry
Independent Director
Independent Director
166.49K
+62.57%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
26.36K
+45.52%
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Gregory A. (Greg) Ciongoli
Mr. Gregory A. (Greg) Ciongoli
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--

よくある質問

Atara Biotherapeutics Incの䞊䜍5名の株䞻は誰ですか


Atara Biotherapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Brian N. Cherry

Atara Biotherapeutics IncATRAの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Atara Biotherapeutics Incの株匏を保有しおいる機関は156瀟あり、保有株匏の総垂堎䟡倀は玄3.70Mで、党䜓の43.48%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-645280.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。